The Liver Meeting Digital Experience™ (TLMdX)

Vaccines against the coronavirus disease 2019 (COVID-19) induce weaker and more transient immune responses in liver transplant recipients, those with cirrhosis, or those with chronic liver disease (CLD), according to a study presented at The Liver Meeting Digital Experience 2021 by the American Association for the Study of Liver Diseases (AASLD 2021).

Liver injury is not uncommon among patients with vaccine breakthrough COVID-19, indicating the importance of monitoring liver injury enzymes, according to a study presented at The Liver Meeting 2021 by the American Association for the Study of Liver Diseases (AASLD 2021).

Tenofovir alafenamide (TAF) yields comparable renal outcomes to tenofovir disoproxil fumarate (TDF) in liver transplant (LT) recipients, according to a study presented at The Liver Meeting Digital Experience 2021 by the American Association for the Study of Liver Diseases (AASLD 2021).

Tenofovir alafenamide (TAF) shows sustained safety and efficacy in heavily pretreated patients with multidrug-resistant hepatitis B virus (HBV) through 3 years of treatment, albeit leading to elevations in cholesterol levels.

Burnout is experienced by nearly half (~40 percent) of hepatology providers during the COVID-19 pandemic, as shown by the negative impact of emotional well-being, including work fulfilment and satisfaction, according to a study.

Switching from tenofovir disoproxil fumarate (TDF) regimens to tenofovir alafenamide (TAF) monotherapy demonstrates long-term efficacy and safety in orthotopic liver transplantation (OLT) recipients with chronic hepatitis B virus (HBV) infection, reports a study presented at The Liver Meeting Digital Experience 2021, by the American Association for the Study of Liver Diseases (AASLD 2021).

The first human pharmacokinetic study of tenofovir alafenamide (TAF; commercially sold as Vemlidy) monotherapy in breastfeeding women with chronic hepatitis B (CHB) has found low concentrations of TAF and tenofovir in the breastmilk, with negligible exposure to infants.